- Home
- KLRS vs CALC Comparison
KLRS vs CALC Comparison
Compare KLRS & CALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KLRS
- CALC
- Stock Information
- Founded
- KLRS 2019
- CALC 2011
- Country
- KLRS United States
- CALC United States
- Employees
- KLRS N/A
- CALC N/A
- Industry
- KLRS Biotechnology: Biological Products (No Diagnostic Substances)
- CALC Biotechnology: Pharmaceutical Preparations
- Sector
- KLRS Health Care
- CALC Health Care
- Exchange
- KLRS Nasdaq
- CALC Nasdaq
- Market Cap
- KLRS 46.0M
- CALC 48.1M
- IPO Year
- KLRS N/A
- CALC N/A
- Fundamental
- Price
- KLRS $2.56
- CALC $2.86
- Analyst Decision
- KLRS Buy
- CALC Strong Buy
- Analyst Count
- KLRS 1
- CALC 2
- Target Price
- KLRS N/A
- CALC $14.50
- AVG Volume (30 Days)
- KLRS 45.1K
- CALC 47.1K
- Earning Date
- KLRS 08-13-2025
- CALC 08-12-2025
- Dividend Yield
- KLRS N/A
- CALC N/A
- EPS Growth
- KLRS N/A
- CALC N/A
- EPS
- KLRS N/A
- CALC N/A
- Revenue
- KLRS N/A
- CALC N/A
- Revenue This Year
- KLRS N/A
- CALC N/A
- Revenue Next Year
- KLRS N/A
- CALC N/A
- P/E Ratio
- KLRS N/A
- CALC N/A
- Revenue Growth
- KLRS N/A
- CALC N/A
- 52 Week Low
- KLRS $2.14
- CALC $1.42
- 52 Week High
- KLRS $24.15
- CALC $5.97
- Technical
- Relative Strength Index (RSI)
- KLRS 49.38
- CALC 52.11
- Support Level
- KLRS $2.37
- CALC $2.74
- Resistance Level
- KLRS $2.58
- CALC $3.00
- Average True Range (ATR)
- KLRS 0.18
- CALC 0.25
- MACD
- KLRS 0.01
- CALC -0.03
- Stochastic Oscillator
- KLRS 64.32
- CALC 74.83
About KLRS Kalaris Therapeutics Inc. Common Stock
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.
About CALC CalciMedica Inc.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys.